Cited by 855Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular DiseasesBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

Hansen, Morten L., Sørensen, Rikke, Clausen, Mette T., Fog-Petersen, Marie Louise, Raunsø, Jakob, Gadsbøll, Niels, Gislason, Gunnar H., Folke, Fredrik, Andersen, Søren S., Schramm, Tina K., Abildstrøm, Steen Z., Poulsen, Henrik E., Køber, Lars, Torp-Pedersen, Christian·2010·Archives of Internal Medicine

DOI 10.1001/archinternmed.2010.271

Open this paper in CoChat — free account

Abstract

BACKGROUND: Patients with atrial fibrillation (AF) often require anticoagulation and platelet inhibition, but data are limited on the bleeding risk of combination therapy. METHODS: We performed a cohort study using nationwide registries to identify all Danish patients surviving first-time hospitalization for AF between January 1, 1997, and December 31, 2006, and their posthospital therapy of warfarin, aspirin, clopidogrel, and combinations of these drugs. Cox proportional hazards models were used to estimate risks of nonfatal and fatal bleeding. RESULTS: A total of 82,854 of 118,606 patients (69.9%) surviving AF hospitalization had at least 1 prescription filled for warfarin, aspirin, or clopidogrel after discharge. During mean (SD) follow-up of 3.3 (2.6) years, 13,573 patients (11.4%) experienced a nonfatal or fatal bleeding. The crude incidence rate for bleeding was highest for dual clopidogrel and warfarin therapy (13.9% per patient-year) and triple therapy (15.7% per patient-year). Using warfarin monotherapy as a reference, the hazard ratio (95% confidence interval) for the combined end point was 0.93 (0.88-0.98) for aspirin, 1.06 (0.87-1.29) for clopidogrel, 1.66 (1.34-2.04) for aspirin-clopidogrel, 1.83 (1.72-1.96) for warfarin-aspirin, 3.08 (2.32-3.91) for warfarin-clopidogrel, and 3.70 (2.89-4.76) for warfarin-aspirin-clopidogrel. CONCLUSIONS: In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding. Dual warfarin and clopidogrel therapy and triple therapy carried a more than 3-fold higher risk than did warfarin monotherapy.

Integrity signals

Registry

Crossref · 10.1001/archinternmed.2010.271

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952
PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
Stroke Prevention in Atrial Fibrillation Study. Final results.
Prevention, S., & Atrial Fibrillation Investigators (1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators* (1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,525
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Canadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. D. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,109

Flagged first, then by citations

Show all 45 references

Sorted by citations

Items 501–600 of 853

The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure
Guo, Y., Lip, G. Y. H., & Apostolakis, S. Z. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9427-y · Cited by 5
“Dual warfarin and clopidogrel therapy and triple therapy (warfarin, aspirin, and clopidogrel) carried a more than threefold higher risk than did warfarin monotherapy [32].”
Background
Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban
Camm, A. J., & Fox, K. A. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1467885 · Cited by 5
“Patients with concomitant AF and ACS are challenging, because the combination of antiplatelet (ASA and/or a P2Y12 inhibitor) and anticoagulation therapy, especially at doses indicated for AF, increases annual risk of fatal and nonfatal bleeding episodes [120-122].”
Background
Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose
Girotra, T., Lowe, F. J., Feng, W., & Ovbiagele, B. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0514-5 · Cited by 4
Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis
Freire, J. L., Lip, G. Y. H., del Blanco, B. G., González, I. F., Mutuberría, M., Alfonso, F., Bueno, H., Cequier, A. R., Prendergast, B., Zueco, J., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.021 · Cited by 5
Anticoagulation for Left Ventricle Thrombus—Case Series and Literature Review for Use of Direct Oral Anticoagulants
Pradhan, A. K., Bhandari, M., Vishwakarma, P., Salimei, C., Iellamo, F., Sethi, R., & Perrone, M. A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10020041 · Cited by 5
“It is well known that combining OACs with DAPTs substantially increases bleeding risk [5,14].”
Background
Optimising interruptive clinical decision support alerts for antithrombotic duplicate prescribing in hospital
Sundermann, M., Clendon, O., McNeill, R., Doogue, M. P., & Chin, P. K. L. (2024) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2024.105418 · Cited by 6
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population
Moras, E., Zaid, S., Gandhi, K., Barman, N., Birnbaum, Y., Virani, S. S., Tamis‐Holland, J. E., Jneid, H. M., & Krittanawong, C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01203-9 · Cited by 7
“A triple antithrombotic treatment (aspirin, P2Y 12 , and anticoagulant) has been associated with an almost four-fold higher risk of bleeding than oral anticoagulation monotherapy [28, 29].”
Clopidogrel in Coronary Artery Disease: Update 2012
Huber, K. (2012) · Advances in cardiology · doi:10.1159/000338051 · Cited by 5
Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI—rationale and study design of the prospective observational multicenter AVIATOR 2 registry
Chandrasekhar, J., Mastoris, I., Baber, U., Sartori, S., Schoos, M. M., Bansilal, S., Dangas, G., & Mehran, R. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.08.023 · Cited by 5
Antithrombotic therapy in patients after valve surgery with special attention to the combination of anticoagulant and antiplatelet therapy
Brtko, M., & Dusek, J. (2013) · Cor et Vasa · doi:10.1016/j.crvasa.2013.01.009 · Cited by 4
“Table 7 – The risk of bleeding with single, dual or triple therapy in patients with atrial fi brillation with warfarin as a reference [29].”
Background
Clopidogrel hydrogen sulphate for atrial fibrillation
Garg, N., Rajpurohit, N., & Flaker, G. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.587118 · Cited by 5
“A large cohort study (82,854 patients) from Denmark evaluated the risk of bleeding associated with different antiplatelet agents and antithrombotic agents in patients with atrial fibrillation [33].”
Background
Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention
Dézsi, C. A., Dézsi, B. B., & Dézsi, D. A. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.01.001 · Cited by 5
Left ventricular thrombosis can still complicate acute myocardial infarction
Tariq, M. U., Tariq, A. M., Tan, C. D., Rodríguez, E. R., & Menon, V. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.14078 · Cited by 5
Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention
Zhao, X.-Y., Li, J., Tang, X., Xu, J., Song, Y., Jiang, L., Chen, J., Song, L., Gao, L., Gao, Z., et al. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.228766 · Cited by 5
“Previous studies showed that the use of the TRA[11] and a low maintenance dose of aspirin may decrease the incidence of bleeding,[14‐16] triple therapy,[17,18] and the use of strong P2Y12 receptor inhibitors may increase the bleeding risk.”
Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI – State-of-the-art review
Gajanana, D., Rogers, T., Iantorno, M., Buchanan, K. D., Ben‐Dor, I., Pichard, A. D., Satler, L. F., Torguson, R., Okubagzi, P. G., & Waksman, R. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.107 · Cited by 5
Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?
Mantis, C., & Alexopoulos, D. K. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.022 · Cited by 5
Utility of Hemoccult Testing Before Therapeutic Anticoagulation in Venous Thromboembolism
Urbas, R., Badri, M., Albert, N. E., Prince, C. T., & Mayilvaganan, B. (2017) · Southern Medical Journal · doi:10.14423/smj.0000000000000650 · Cited by 5
The Association between the PRECISE-DAPT Score and New-Onset Atrial Fibrillation in Patients with ST-Elevation Myocardial Infarction
Pamukçu, H. E., Tanık, V. O., Şimşek, B., & Güllü, İ. H. (2021) · The Journal of Tehran University Heart Center · doi:10.18502/jthc.v16i1.6596 · Cited by 5
Clopidogrel Or Ticagrelor Alongside Dabigatran in Acute Coronary Syndrome and Indication for NOAC: A Study Rationale
Luijkx, J. J. P., Winkler, P. J. C., & Hof, A. W. J. V. ’. (2021) · Future Cardiology · doi:10.2217/fca-2021-0085 · Cited by 5
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making
McClure, G. R., Kaplovitch, E., Chan, N., & Anand, S. S. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.02.018 · Cited by 5
The safety of continuous fascia iliaca block in patients with hip fracture taking pre-injury anticoagulant and/or antiplatelet medications
Sucher, J. F., Barletta, J. F., Shirah, G. R., Prokuski, L. J., Montanarella, P. D., Dzandu, J. K., & Mangram, A. J. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.08.019 · Cited by 5
[The evaluation and treatment of a patient with atrial fibrillation].
Moreno-Ruíz, L. A., Rodríguez-Piña, H., & Martínez-Flores, J. E. (2012) · PubMed · Cited by 5
Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation
Xiong, Q., Lau, Y. C., & Lip, G. Y. H. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1027683 · Cited by 5
“In patients with AF requiring both anticoagulation and antiplatelet therapy, increased bleeding risk has been noted with combinations of warfarin with aspirin and/or clopidogrel [74].”
Background
Relationship of hospital-associated bleeding with length of stay and total hospitalization costs in patients hospitalized for atrial fibrillation
Amin, A., Robinson, S. B., Bowdy, B. D., Jing, Y., Johnson, B. H., & Wiederkehr, D. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1134545 · Cited by 5
Impact of Anticoagulation in Elderly Patients With Pulmonary Embolism That Undergo IVC Filter Placement: A Retrospective Cohort Study
Falatko, J., Dalal, B., & Qu, L. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.01.011 · Cited by 5
Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Mishra, A., Singh, M., Acker, W. W., Kamboj, S., Sporn, D., Stapleton, D. D., & Kaluski, E. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000697 · Cited by 7
Clinical benefits and risks of antithrombotic therapy in patients with atrial fibrillation with comorbidities – A report from the CHART-2 Study
Shiroto, T., Sakata, Y., Nochioka, K., Abe, R., Kasahara, S., Sato, M., Aoyanagi, H., Fujihashi, T., Yamanaka, S., Hayashi, H., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.09.022 · Cited by 5
How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018
de Veer, A. J. W. M., Bennaghmouch, N., Dewilde, W. J. M., & ten Berg, J. M. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01500-3 · Cited by 6
Medication Nonadherence
Baber, U., Blaha, M. J., & Mehran, R. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.010 · Cited by 5
Duale Plättchenhemmung in der Intensivmedizin
Siller-Matula, J. M., & Karth, G. D. (2014) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-014-0394-8 · Cited by 5
Acute gastrointestinal bleeding after percutaneous coronary intervention
Wallace, M. C., Rankin, J. M., & Forbes, G. M. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.104 · Cited by 5
Plasma complement 3d levels in the early phase after pancreas transplantation.
Suermann, A., Vonend, O., Schenker, P., Viebahn, R., Rump, L. C., & Weiner, S. M. (2009) · PubMed · Cited by 5
Antithrombotic Management in Patients with Prosthetic Valves
Butchart, E. G., & Caterina, R. D. (2012) · Wiley eBooks · doi:10.1002/9781118410875.ch17 · Cited by 5
Timing of anticoagulation restart after serious bleeding in atrial fibrillation
Al‐Hussainy, N. R., Kragholm, K. H., Lundbye‐Christensen, S., Torp-Pedersen, C., Pareek, M., Therkelsen, S. K., Lip, G. Y. H., & Riahi, S. (2025) · Heart · doi:10.1136/heartjnl-2024-325343 · Cited by 4
“30 This is in line with our analysis, where the risk of recurrent bleeding was highest if DOAC was combined with antiplatelet agents.”
Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding
Hozman, M., Hassouna, S., Grochol, L., Waldauf, P., Hráček, T., Pazdiorova, B. Z., Adamec, S., & Osmancik, P. P. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad103 · Cited by 4
“However, the association between AT therapy and UGB was well documented.(3,4) The most common indications for ATs are cardiovascular disorders, in particular coronary artery disease (CAD), atrial fibrillation (AF), and thromboembolic disease.”
Background
Anticoagulation in Patients with Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization
Kim, T. I., DeWan, A. T., Murray, M., Wang, H., Mani, A., Mena‐Hurtado, C., Guzman, R. J., & Chaar, C. I. O. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.02.006 · Cited by 4
Grace periods and exposure misclassification in self-controlled case-series studies of drug–drug interactions
Zhang, H., Bilker, W. B., Leonard, C. E., Hennessy, S., & Miano, T. A. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae231 · Cited by 4
Optimal Duration of Anticoagulant Therapy
Schulman, S. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1333542 · Cited by 4
Thrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary intervention
Николаевна, К. Е., Станиславовна, К. Е., Панченко, Е. П., & Samko, A. N. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.09.000297 · Cited by 4
“Комбинация антикоагулянтной и антиагрегантной терапии повышает риск кровотечений более чем в 3 раза [16].”
Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation
Subat, Y. W., Rayes, H., Hanson, A. C., Johnson, M. Q., Schulte, P. J., Evans, K. D., Weister, T. J., Trivedi, V., Gajic, O., & Warner, M. A. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.003 · Cited by 4
“While prior investigations in non-critically ill populations have demonstrated an increased risk of bleeding with concomitant use of antiplatelet agents and therapeutic anticoagulation, the relationship between concomitant therapy and major bleeding in critically ill populations remains undefined.[10, 11] Further, the…”
BackgroundResult
Antithrombotic management in atrial fibrillation patients following percutaneous coronary intervention: A clinical review
Saito, Y., & Kobayashi, Y. (2024) · Journal of Arrhythmia · doi:10.1002/joa3.13128 · Cited by 4
Potential role of rivaroxaban in patients with acute coronary syndrome
Fitchett, D. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s30342 · Cited by 4
“8) when dual antiplatelet therapy is added to warfarin.(11) Consequently, any potential net benefit of warfarin in ACS should take into account the increased bleeding risk from dual antiplatelet therapy in the context of an early invasive strategy.”
Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations
Coons, J. C., & Miller, T. J. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1447 · Cited by 5
“The most notable limitation, however, may be the excess bleeding observed relative to earlier studies.(2) This may be a reflection of the study design in the WOEST trial to capture any bleeding episode, rather than just major bleeding, and the relatively high (~65%) use of DES.”
Result
Antithrombotic Therapy During and After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation
Verheugt, F. W. A. (2013) · Circulation · doi:10.1161/circulationaha.113.002250 · Cited by 4
“When dual antiplatelet therapy was combined with warfarin, bleeding increased by 50% in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial(7) and 100% to 400% in a large Danish registry.(8,9)”
Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta‐analysis
Agasthi, P., Lee, J. Z., Pujari, S. H., Tseng, A. S., Shipman, J. N., Almader‐Douglas, D., Ashraf, H., Mookadam, F., Fortuin, F. D., Beohar, N., et al. (2020) · Journal of Arrhythmia · doi:10.1002/joa3.12292 · Cited by 3
“All-cause death 35 per 1000 39 per 1000 (31-50) RR 1.”
Left Atrial Appendage Occlusion for Patients with Transcatheter Aortic Valve Replacement, MitraClip, Percutaneous Coronary Intervention, and Ablation for Atrial Fibrillation
Krishnaswamy, A., Wazni, O. M., & Kapadia, S. R. (2020) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2019.11.006 · Cited by 4
Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation
Kook, H., Kim, H.-D., Uhm, J., Kim, Y., Kim, J., Pak, H., Lee, H., Choi, R. K., Kang, W. C., Shin, E., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244723 · Cited by 4
“In a Danish registry, major bleeding events occur primarily during the early period of medication, mostly within 3 months from the onset of TAT [2, 4].”
Background
Inappropriate Use of Oral Antithrombotic Combinations in an Outpatient Setting and Associated Risks: A French Nationwide Cohort Study
Zerah, L., Bonnet‐Zamponi, D., AJROUCHE, A., Collet, J., Rycke, Y. D., & Tubach, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112367 · Cited by 4
“This definition, usually used in studies using healthcare databases [3,21,22], is a pragmatic way to identify severe bleeding events from a patient perspective (bleeding requiring in-hospital care and/or with consequences leading to hospitalization).”
BackgroundInfluential
Direct Oral Anticoagulation Versus Warfarin in Left Ventricular Thrombus: Pooled Analysis of Randomized Controlled Trials
Sahlén, A. O., Jiang, H., Lau, Y. H., Cuenza, L. R., Cader, F. A., Al-Omary, M. S., Surunchupakorn, P., Ho, K. H., Sung, J. G., Lee, D. P. H., et al. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2267 · Cited by 4
Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study
Hwang, Y. J., Chang, H., Metkus, T. S., Andersen, K. M., Singh, S., Alexander, G. C., & Mehta, H. B. (2023) · Drug Safety · doi:10.1007/s40264-023-01388-z · Cited by 4
“Such combined antithrombotic strategy poses significant risk for bleeding [2, 3].”
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction
Coons, J. C., Schwier, N. C., Harris, J. R., & Seybert, A. L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.890589 · Cited by 4
“In fact, the annualized rate of fatal and nonfatal bleeding in patients who require ‘triple antithrombotic therapy’ has been reported to be 4 -- 16% [49-51].”
Background
Atrial fibrillation in older patients-reducing stroke risk is not only about anticoagulation.
Win, N. T., & Teo, S. P. (2016) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2016.10.004 · Cited by 4
The prescription of antiplatelet medication in a very elderly population: An observational study in 15 141 ambulatory subjects
Manckoundia, P., Buzens, J.-B., Mahmoudi, R., d’Athis, P., Martin, I. P., Laborde, C., Menu, D., & Putot, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.13020 · Cited by 4
Effectiveness and safety of omega-3 fatty acids for the prevention of ischemic complications following carotid artery stenting: An early terminated pilot study.
Foroughinia, F., Jamshidi, E., Javanmardi, H., Safari, A., & Borhani‐Haghighi, A. (2018) · Europe PMC (PubMed Central) · Cited by 4
Impact of a Prescription Support Tool to Improve Adherence to the Guidelines for the Prescription of Oral Antithrombotics: The Combi-AT Randomized Controlled Trial Using Clinical Vignettes
Zerah, L., Bonnet‐Zamponi, D., Dechartres, A., Frappé, P., Hauguel‐Moreau, M., Collet, J., Rycke, Y. D., & Tubach, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111919 · Cited by 4
“AT combinations greatly increase this risk, especially when oral anticoagulation is combined with antiplatelet agents [4,5].”
Background
Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial
Takahashi, K., Kogame, N., Tomaniak, M., Chichareon, P., Chang, C. C., Modolo, R., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., et al. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01585-w · Cited by 4
Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation
Nagaraj, T. A., Snider, M. J., Davidson, E. R., Weiss, R., Li, J., & Afzal, M. R. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020916638 · Cited by 4
Optimal antiplatelet and anticoagulation strategies in acute coronary syndromes
Rath, D., & Geisler, T. (2020) · Herz · doi:10.1007/s00059-020-04947-7 · Cited by 3
The Current Perspectives on Coronary Artery Bypass Grafting
Murashita, T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83055 · Cited by 4
İnme klinik pratiğinde NOAK kullanımı: Türk Beyin Damar Hastalıkları Derneği Uzman Görüşü
Acar, B. A., Akpınar, Ç. K., Alioğlu, Z., Arlıer, Z., Arsava, E. M., Aytaç, E., Baş, D. F., Baydemir, R., Çabalar, M., Çevik, M. U., et al. (2020) · Turkish Journal of Cerebrovascular Diseases · doi:10.5505/tbdhd.2020.26213 · Cited by 4
Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users
Kawano, Y., Nagata, M., Nakamura, S., Akagi, Y., Suzuki, T., Tsukada, E., Hoshiko, M., Kujirai, A., Nakamatsu, S., Nishikawa, T., et al. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00791 · Cited by 4
Gastrointestinale Blutung
Pohlmann, A., Trebicka, J., Götz, M., & Steurer, M. (2018) · Gastroenterologie up2date · doi:10.1055/s-0043-121449 · Cited by 4
“Neuere Agenzien, die nur im Rahmen von klinischen Studien zum Einsatz kommen, sind beispielsweise bovine Gerinnungsfaktoren oder ein synthetisches Aminosäuregel.”
Influential
Who Gets Stroke Prevention? Stroke Prevention in Atrial Fibrillation Patients in the Inpatient Setting
Gallagher, R. D., Roach, K., Sadler, L., Belshaw, J., Kirkness, A., Zhang, L., Proctor, R., & Neubeck, L. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.12.010 · Cited by 4
“Indeed, many patients with AF and coronary heart disease may be on dual anti-platelet therapy in combination with an oral anticoagulant [22].”
BackgroundInfluential
Current therapy of non-ST-elevation acute coronary syndromes.
Paxinos, G., & Katritsis, D. G. (2012) · PubMed · Cited by 4
High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting
Rilinger, J., Meyer, M., Schnabel, K., Weik, P., Charlet, A., Esser, J., Zhou, Q., Bode, C., Moser, M., Diehl, P., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1397-5 · Cited by 4
“In fact, a combined approach—so called triple therapy (TT)—is one of the standard procedures reducing thromboembolic events at the cost of a high bleeding risk [8, 9].”
Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study
Tarantino, G., Capone, D., Contaldi, P., Gianno, A., Mosca, T., & Tufano, A. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617733040 · Cited by 4
“Adverse events of warfarin therapy include bleeding episodes involving in particular, the gastrointestinal (GI) and urinary tract and the risk of cerebral hemorrhage is the most fearsome complication in particular in elderly patients.(10,11) As known, the relationship between the dose of warfarin and the response is m…”
Background
Periinterventionelles Management der Antikoagulation und Antiaggregation
Nagler, M., Erné, P., Babst, R., Korte, W., & Wuillemin, W. A. (2011) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2011.07539 · Cited by 4
New Possibilities in the Treatment of Patients With Stable Manifestations of Atherothrombosis
Панченко, Е. П. (2017) · Kardiologiia · doi:10.18087/cardio.2017.12.10060 · Cited by 4
Dual versus single antiplatelet therapy for patients with long-term oral anticoagulation undergoing coronary intervention: a systematic review and meta-analysis.
Yu, J., Zou, C., Liu, W., & Yang, G. (2017) · PubMed Central · doi:10.11909/j.issn.1671-5411.2017.12.002 · Cited by 4
Causality Discovery with Domain Knowledge for Drug-Drug Interactions Discovery
Subpaiboonkit, S., Li, X., Zhao, X., Scells, H., & Zuccon, G. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-35231-8_46 · Cited by 4
New Oral Anticoagulants in Atrial Fibrillation Forever?
Verheugt, F. W. A. (2013) · Circulation · doi:10.1161/circulationaha.113.003825 · Cited by 4
Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding
Ghattas, A., Shantsila, E., & Lip, G. Y. H. (2011) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710397225 · Cited by 4
Long-term antithrombotic therapy after coronary artery bypass grafting in patients with preoperative atrial fibrillation. A nationwide observational study from the SWEDEHEART registry
Skibniewski, M., Venetsanos, D., Ahlsson, A., Batra, G., Friberg, Ö., Hofmann, R., Janzon, M., Karlsson, L., Lawesson, S. S., Nielsen, S. J., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.12.001 · Cited by 3
“37 , 38 Increased Increased bleeding risk with the combination of PI + OAC compared with OAC alone has been shown also when a direct oral anticoagulant (DOAC) was used as OAC.”
Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
Springer, A. N., Alicea, L. A., Gafari, Y., Smith, T. B., Lynch, S. E., Breman, A. M., Hodge, J. C., Pratt, V. M., Powell, N. R., Kreutz, R. P., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3698 · Cited by 3
Development of an interpretable machine learning model to predict short-term bleeding risk in patients receiving dual antithrombotic therapy following cardiac surgery
Han, H., Zhang, J., Wang, X., Ge, W., & Qu, J. Z. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-02016-9 · Cited by 3
A Grateful but Not Passive Patient
Rifkin, E., & Lazris, A. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3569 · Cited by 3
Percutaneous left atrial appendage closure in patients with gastrointestinal bleeding associated with oral anticoagulants
Segura, P. S., Sánchez, J. J., Arbonés-Mainar, J. M., Lezcano, J. S.-R., Osuna, G. G., & Monterde, V. B. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2239973 · Cited by 3
“Its association with acetylsalicylic acid doubles the risk of VKA in monotherapy [6].”
Background
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
Eikelboom, J. W., & Connolly, S. J. (2015) · Cardiology Research · doi:10.14740/cr413w · Cited by 2
“DAPT is required to prevent stent thrombosis but the combination of a VKA and DAPT greatly increases the risk of bleeding [56, 57].”
Background
Prevention of Thromboembolism in Atrial Fibrillation Patients
Kuzniatsova, N., & Lip, G. Y. H. (2011) · European Cardiology Review · doi:10.15420/ecr.2011.7.1.37 · Cited by 3
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice
Łukasik, M., Zawilska, K., & Undas, A. (2015) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2015.04.007 · Cited by 3
“[27] Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Godsboll N, et al.”
Background
Safety and efficacy of anti-thrombotic regimens in patients with percutaneous coronary intervention requiring oral anticoagulation: A traditional and network meta-analysis
Khan, S. U., Saleem, M. A., Abdullah, A., Ghimire, S., Lekkala, M. R., Rahman, H., Lone, A. N., & Kaluski, E. (2017) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2017.04.008 · Cited by 4
Antiplatelet Treatment for Catheter-Based Interventions in High-Risk Patients: Current Guidelines and Expert Opinion
Rath, D., & Gawaz, M. (2018) · Hämostaseologie · doi:10.1055/s-0038-1668165 · Cited by 3
Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice
Clarke, A., Ibrahim, A., & Kiernan, T. J. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1521721 · Cited by 3
Pharmacodynamic safety of clopidogrel monotherapy in patients under oral anticoagulation with a vitamin K antagonist undergoing coronary stent implantation
Valina, C. M., Bömicke, T., Abd-Elrazek, S., Eltaweel, S., Stratz, C., Ferenc, M., Trenk, D., Chafai, A., Neumann, F., & Hochholzer, W. (2018) · Platelets · doi:10.1080/09537104.2018.1506099 · Cited by 3
“Therefore, it is not surprising that the number of patients needing oral anticoagulation is rising – as well as the risk for bleeding in patients needing a combination of antiplatelet therapy and OAC (3,9,10).”
Background
Implementation of a standardised annual anticoagulation specialist review in primary care
Hutchinson-Jones, N., Didcott, S. K., Jones, M. D., & Crowe, J. (2020) · Primary Health Care Research & Development · doi:10.1017/s1463423620000171 · Cited by 3
Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy–An observational study
Holm, A., Henriksson, M., Alfredsson, J., Janzon, M., Johansson, T., Swahn, E., Vial, D., & Lawesson, S. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248359 · Cited by 4
“7% of bleeds leading to hospitalisation or death in TAT treated AF patients [17].”
BackgroundResult
Dual antithrombotic therapy and gastroprotection in atrial fibrillation: an observational primary care study
Xie, C. X., Robson, J. P., Williams, C., Carvalho, C., Rison, S. C. G., & Raisi‐Estabragh, Z. (2022) · BJGP Open · doi:10.3399/bjgpo.2022.0048 · Cited by 3
“0% (351) were prescribed a PPI/H2RA, which is higher than reported by other cohort studies (11%-63%).([25,27,28]) We achieved a relatively high figure possibly by virtue of a local incentive program promoting the use of PPI optimization, or simply because contemporary guidance and research is more likely to endorse th…”
Result
Gastrointestinale Blutungen
Meier, B., & Caca, K. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1813-3801 · Cited by 3
“Noch höher ist das Risiko unter Vollantikoagulation, wobei das Blutungsrisiko unter der Einnahme von VitaminKAnt agonisten, wie z. B. Marcumar, mit der Einnahme von direk ten oralen Antikoagulantien (DOAK) vergleichbar ist [10].”
Influential
Contribution of biopharmaceutics and pharmacokinetics to improve drug therapy
Sen, K. K., Sinha, D., Nayak, A. K., & Sen, S. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91818-3.00023-2 · Cited by 3
Evaluation of a prescription support-tool for chronic management of oral antithrombotic combinations in adults using clinical vignettes: protocol of a randomised controlled trial
Zerah, L., Bonnet‐Zamponi, D., Frappé, P., Hauguel‐Moreau, M., Rycke, Y. D., Magnier, A., Pautas, É., Charles, P., Collet, J., Dechartres, A., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025544 · Cited by 3
“7-fold higher risk with triple therapy (warfarin, aspirin and clopidogrel) than warfarin monotherapy in patients with non-valvular atrial fibrillation.(5) So far, no study has evaluated the rate of prescriptions of AT combinations not complying with guidelines for adults, taking strengths and limitations of this study”
Background
Anti-thrombotic therapy strategies with long-term anticoagulation after percutaneous coronary intervention – a systematic review and meta-analysis
Siddiqui, W. J., Khan, M. Y., Rawala, M. S., Jethwani, K., Khan, M. H., Alvarez, C., Kashif, R., Hasni, S. F., Aggarwal, S., Kohut, A. R., et al. (2019) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1611330 · Cited by 3
Evolution of Antithrombotic Management of Atrial Fibrillation After Percutaneous Coronary Intervention Over 10 Years and Guidelines Uptake
Beaulieu, M.-C., Boivin‐Proulx, L., Matteau, A., Mansour, S., Gobeil, J., & Potter, B. J. (2021) · CJC Open · doi:10.1016/j.cjco.2021.04.002 · Cited by 4
Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?
Rajagopalan, B., & Curtis, A. B. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022495 · Cited by 3
“In patients requiring triple therapy, studies have demonstrated an increased risk of major and minor bleeding [20,21].”
Background
Konsensus-Statement – Schlaganfallprophylaxe bei nicht-valvulärem Vorhofflimmern unter besonderer Berücksichtigung der direkten oralen Antikoagulanzien
(ÖKG), Ö. K. G., Pabinger, I., (OeGHO), Ö. G. F. H. &. M. O., (ÖGSF), Ö. S.-G., (ÖGIM), Ö. G. F. I. M., Anästhesiologie, Ö. G. F., (ÖGARI), R. U. I., (ÖGAM), Ö. G. F. A. U. F., Lang, W., Roithinger, F. X., et al. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0586-5 · Cited by 3
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil
Lópes, R. D., Becker, R. C., Alexander, J. H., Armstrong, P. W., Califf, R. M., Chan, M. Y., Crowther, M. A., Granger, C. B., Harrington, R. A., Hylek, E. M., et al. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0592-7 · Cited by 3
Manejo de los nuevos anticoagulantes orales (NACO) en hemorragia digestiva y procedimientos endoscópicos
del Molino, F., González, I. M., & Saperas, E. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.02.014 · Cited by 3
Optimizing selection of antithrombotic therapy in patients requiring PCI and long term anticoagulation
Edupuganti, M. M. R., Marmagkiolis, K., Çilingiroğlu, M., Uretsky, B. F., & Hakeem, A. (2014) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2014.07.006 · Cited by 3
“9% surviving AF hospitalization had at least 1 prescription filled for warfarin, aspirin, or clopidogrel after discharge [19].”
Background
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: Necessary or too hazardous?
Verheugt, F. W. A. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.01.018 · Cited by 3
Venous Thromboembolism and Postoperative Management of Anticoagulation
Friedman, S. M., & Uy, J. D. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.01.007 · Cited by 3
“A patient taking aspirin in addition to warfarin has almost twice the risk of bleeding, and a patient on both aspirin and clopidogrel in addition to warfarin has 4 times the risk.(23) The optimal duration of prophylaxis is unclear.”
Background
Triple Antithrombotic Therapy and Outcomes in Post‐PCI Patients Undergoing Non‐cardiac Surgery
Valle, J. A., Graham, L. A., DeRussy, A. J., Itani, K. M. F., Hawn, M. T., & Maddox, T. M. (2016) · World Journal of Surgery · doi:10.1007/s00268-016-3725-5 · Cited by 3
“While two prior studies demonstrate reduction of adverse cardiac events with triple therapy [1, 4], four demonstrated no relationship with outcomes [2, 3, 6, 26].”
Result

Authors: Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., Abildstrøm, S. Z., Poulsen, H. E., Køber, L., & Torp-Pedersen, C.
Affiliations: Copenhagen University Hospital (DK)
ORCID: Hansen, Morten L.
Sørensen, Rikke
Raunsø, Jakob
Gislason, Gunnar H.
Folke, Fredrik
Poulsen, Henrik E.
Køber, Lars
Torp-Pedersen, Christian
Venue: Archives of Internal Medicine
Publisher: American Medical Association (AMA)
Published: 2010-09-13
Volume: 170
Issue: 16
Pages: 1433-41
ISSN: 0003-9926 (ISSN-L)
DOI: 10.1001/archinternmed.2010.271
OpenAlex: W2144471064
Cited by: 855
References: 45
Citations by year: 2026: 16 · 2025: 23 · 2024: 23 · 2023: 25 · 2022: 41 · 2021: 37 · 2020: 64 · 2019: 83 · 2018: 63 · 2017: 75 · 2016: 80 · 2015: 68 · 2014: 63 · 2013: 76 · 2012: 63
FWCI: 42.19
Type: journal article
Language: en
Open access: closed
Locations: Archives of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords: atrial fibrillation, bleeding risk, warfarin, aspirin, clopidogrel, combination antithrombotic therapy, triple therapy, dual therapy, anticoagulation, platelet aggregation inhibition, fatal bleeding
MeSH terms: Clopidogrel, Aged, Anticoagulants, Aspirin, Atrial Fibrillation, Brain Ischemia, Denmark, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Registries, Risk, Ticlopidine, Warfarin, Cohort Studies, Comorbidity, Incidence, Proportional Hazards Models, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks